Hypothesis

Restoring TET-mediated DNA demethylation in senescent CD8+ T cells reprograms their SASP from a pro-inflammatory to a tissue-reparative profile, thereby converting these cells from drivers of inflammaging into active contributors to homeostasis without requiring their elimination.

Mechanistic Rationale

Age-associated decline in TET1/TET3 reduces 5hmC at promoters of anti-inflammatory genes (e.g., IL10, TGFB1) and enhances methylation of pro-inflammatory SASP components (e.g., IL6, IL1B). This epigenetic shift locks senescent T cells into a secretory state that fuels chronic inflammation. Conversely, TET activity can demethylate enhancers of regenerative pathways (e.g., AREG, VEGFA) while preserving cytotoxic granules (GZMK) that support tumor surveillance. Thus, the senescent T cell’s functional output is epigenetically tunable rather than fixed.

Testable Predictions

1. Pharmacologic activation of TET (e.g., with vitamin C or alpha-KG analogs) in aged human PBMCs will increase 5hmC at IL10 and TGFB1 loci and decrease 5hmC at IL6 and IL1B promoters in the senescent CD8+ CD28- CD27- subset.
2. This epigenetic shift will correlate with a measurable reduction in SASP-induced NF-kB signaling in co-cultured fibroblasts and a concomitant increase in fibroblast proliferation and collagen deposition.
3. Senescent T cells treated with TET activators will retain granzyme-K expression and cytotoxic capacity against tumor cell lines, but will exhibit reduced capacity to drive endothelial activation (VCAM-1/ICAM-1 upregulation).
4. In vivo, aged mice receiving TET-activating nanoparticles targeted to CD8+ T cells will show lower serum IL-6, higher tissue repair markers after injury, and unchanged tumor surveillance compared with senolytic-treated controls.

Experimental Approach

• Isolate senescent CD8+ T cells from young (3 mo) and aged (24 mo) mice using CD44high CD62Llow CD28- CD27- markers.
• Treat ex vivo with vitamin C (50 µM) or cell-permeable alpha-KG for 48 h.
• Measure 5hmC by dot-blot or oxBS-seq at selected promoters.
• Quantify SASP cytokines via multiplex ELISA.
• Assess fibroblast proliferation (EdU incorporation) and collagen synthesis (Sirius Red) in transwell co-culture.
• Evaluate cytotoxic function using ^51Cr release against YAC-1 targets.
• For in vivo validation, inject lipid-nanoparticles encapsulating vitamin C conjugated to anti-CD8 antibody into aged mice; monitor serum cytokines, histology of wound healing models, and tumor challenge with MC38 cells.

Potential Confounds and Controls

• Vitamin C also acts as an antioxidant; include N-acetylcysteine control to differentiate redox vs. demethylation effects.
• Verify that observed changes are not due to selective cell death using Annexin V/PI staining.
• Use TET1/TET3 conditional knockout T cells as a negative control to confirm dependence on demethylation.

If these predictions hold, senescent T cells would be reinterpreted as epigenetically programmable immunomodulators, suggesting that therapeutic strategies aimed at modifying their SASP—rather than ablating them—could ameliorate inflammaging while preserving protective immunity.